You are here

  • Home
  • Archive
  • Volume 9, Issue 8
  • Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

 

Online download statistics by month:

Online download statistics by month: August 2021 to July 2025

AbstractFullPdf
Aug 2021974986239
Sep 2021463464118
Oct 202121321374
Nov 202120020075
Dec 202113513660
Jan 202212913260
Feb 20229410775
Mar 202214715973
Apr 202217318444
May 202214715171
Jun 20229410049
Jul 202212012558
Aug 202214515068
Sep 202216416983
Oct 202213413868
Nov 202210010263
Dec 202210710775
Jan 202311611643
Feb 202312612654
Mar 202314414778
Apr 2023848450
May 202310410662
Jun 202354855059
Jul 2023757555
Aug 2023899147
Sep 2023979882
Oct 202310010060
Nov 202310911457
Dec 202311912074
Jan 202412512881
Feb 202413113165
Mar 2024157162201
Apr 202415115292
May 2024137144112
Jun 202413914390
Jul 202413914173
Aug 202413112976
Sep 202412912981
Oct 202415715884
Nov 202412313283
Dec 2024186189100
Jan 2025139140100
Feb 2025173174117
Mar 202515215283
Apr 2025214214124
May 2025142142121
Jun 202510711060
Jul 2025110
Total788380213817